SAN DIEGO, June 11, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP announces that a class action lawsuit has commenced on behalf of investors of Fortrea Holdings Inc. (NASDAQ: FTRE). The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) Fo ...

Core Viewpoint - Fortrea has appointed Anshul Thakral as CEO, effective August 4, 2025, succeeding Interim CEO Peter M. Neupert, who will remain as chairman of the board [3][4]. Company Leadership - Anshul Thakral brings over 20 years of experience in life sciences, focusing on executing Fortrea's transformation plan and enhancing profitable growth [4][6]. - Neupert praised Thakral's leadership capabilities, industry knowledge, and commitment to innovation, indicating he is well-suited to lead Fortrea [5]. Strategic Focus - Thakral aims to modernize the clinical trials process and enhance customer engagement while delivering profitable growth and value for shareholders [5][6]. - Fortrea is recognized for its strong reputation in scientific rigor and customer experience, which Thakral intends to build upon [5][6]. Company Background - Fortrea is a leading global contract research organization (CRO) that partners with biopharmaceutical, biotechnology, and medical device companies to accelerate healthcare innovation [7]. - The company offers comprehensive clinical trial management and consulting services, leveraging over 30 years of experience across more than 20 therapeutic areas [7].

BENSALEM, Pa., June 11, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ: FTRE).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN FORTREA HOLDINGS INC. (FTRE), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE AUGUST 1, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Contact the Law Offi ...

Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings, Inc. for allegedly making false and misleading statements regarding its financial performance and business prospects during the Class Period from July 3, 2023, to February 28, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Fortrea overestimated revenue contributions from Pre-Spin Projects and overstated cost savings from exiting transition service agreements, leading to inflated EBITDA targets for 2025 [5]. - It is alleged that Fortrea's public statements were materially false and misleading, which resulted in investor damages when the true details became known [5]. Group 2: Participation Information - Investors who purchased Fortrea securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can visit the provided link or contact the Rosen Law Firm for more information [3][6].

Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding its financial performance and business model following its spin-off from Labcorp Holdings Inc. [1][3] Company Overview - Fortrea is a global clinical research organization (CRO) that provides development solutions for biopharmaceutical products and medical devices [2]. - The company was spun off from Labcorp in June 2023, with ongoing long-term projects at the time of the spin-off [2]. Allegations of the Lawsuit - The lawsuit claims that Fortrea overestimated revenue contributions from pre-spin projects and overstated cost savings from exiting transition services agreements (TSAs) [3]. - It is alleged that Fortrea's EBITDA targets for 2025 were inflated, leading to an overstatement of the company's business viability and financial prospects [3]. Impact of Analyst Reports - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in its business model and a lack of material cost savings from exiting TSAs, resulting in a stock price drop of over 12% [4]. - Following the cancellation of two scheduled conferences, Baird Equity Research downgraded Fortrea to neutral from outperform on December 6, 2024, leading to an 8% decline in stock price [5]. Financial Performance Disclosure - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not aligned with prior expectations, revealing that pre-spin projects were underperforming [6]. - The announcement led to a significant stock price drop of over 25% [6].

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Fortrea Holdings Inc. ("Fortrea Holdings Inc." or the "Company") (NASDAQ: FTRE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fortrea Holdings Inc. investors who were adversely affected by alleged securities fraud between July 3, 2023 and February 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/psl ...

Core Viewpoint - Fortrea Holdings Inc. is facing potential legal claims due to allegations of misleading statements regarding its financial performance and business model, particularly related to its Pre-Spin Projects and cost savings from exiting Transitional Service Agreements (TSAs) [4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is investigating claims against Fortrea and has set an August 1, 2025 deadline for investors to seek lead plaintiff status in a federal securities class action [2]. - Investors who suffered losses in Fortrea between July 3, 2023, and February 28, 2025, are encouraged to contact the firm to discuss their legal options [1]. Group 2: Financial Performance and Stock Price Impact - The complaint alleges that Fortrea overestimated revenue contributions from Pre-Spin Projects and overstated cost savings from exiting TSAs, leading to inflated EBITDA targets for 2025 [4]. - Following a downgrade by Jefferies on September 25, 2024, Fortrea's stock price fell by $2.73, or 12.29%, closing at $19.48 per share [5]. - A subsequent downgrade by Baird on December 6, 2024, after the cancellation of two conferences, resulted in a further stock price decline of $1.90, or 8.06%, closing at $21.67 per share [6]. - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA expectations for 2025 were not aligned with prior forecasts, leading to a significant stock price drop of $3.47, or 25.05%, closing at $10.38 per share [7].

Fortrea is a global contract research organization that provides biopharmaceutical product and medical device development solutions. In June 2023, Fortrea was spun off into a standalone, publicly traded company by Labcorp Holdings Inc. ("Labcorp"). In connection with the spin-off, Fortrea entered into several transition services agreements (the "TSAs"), pursuant to which it agreed to pay Labcorp for certain transitional services over a set period. As alleged, Fortrea discussed the significant cost savings a ...

NEW YORK, June 10, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fortrea Holdings Inc. ("Fortrea Holdings Inc." or the "Company") (NASDAQ: FTRE) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fortrea Holdings Inc. investors who were adversely affected by alleged securities fraud between July 3, 2023 and February 28, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/f ...

Red Cat Holdings, Inc. (NASDAQ: RCAT) - Class action lawsuit initiated for stockholders covering the period from March 18, 2022, to January 15, 2025, with a lead plaintiff deadline of July 22, 2025 [2] - Allegations include misleading statements regarding the production capacity of Red Cat's Salt Lake City facility and the value of the Short Range Reconnaissance Program contract [3][4] - On July 27, 2023, Red Cat disclosed that its facility could only produce 100 drones per month, leading to a nearly 9% drop in stock price [4] - Financial results for Q1 FY2025 revealed losses per share of $0.17, missing estimates by $0.09, and revenue of $2.8 million, missing by $1.07 million, causing a more than 25% decline in stock price [5] - A report from Kerrisdale Capital on January 16, 2025, claimed the SRR contract was less favorable than previously indicated, resulting in a stock price drop of over 21% [6] Fortrea Holdings Inc. (NASDAQ: FTRE) - Class action lawsuit initiated for stockholders covering the period from July 3, 2023, to February 28, 2025, with a lead plaintiff deadline of August 1, 2025 [7] - Fortrea was spun off from Labcorp Holdings Inc. in June 2023, and entered into transition services agreements with Labcorp [7] - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA expectations for 2025 were not aligned with prior forecasts, leading to a stock price drop of 25.05% [8] - Allegations include overestimating revenue from Pre-Spin projects and overstating cost savings from exiting TSAs, which inflated EBITDA targets and overstated the viability of the post-Spin-Off business model [9]